Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
Adam Feuerstein
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.